Relationship between serum thyroid stimulating hormone and papillary thyroid micrcarcinomas_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

Qiamixi·BIEZIERJIAN , Halimulati·MUERTIZHA ,  Sailike·MAGAOWEIYA , Haerman·AJIHAN

Department of Vascular and Thyroid Surgery, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, P. R. China;

Corresponding?author：

Sailike·MAGAOWEIYA, Email: sairike@126.com

Keywords：

thyrotropin; malignant neoplasm of thyroid; papillary thyroid microcarcinoma; nodular goiter

DOI：

10.7507/1007-9424.201603075

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the relationship between thyroid stimulating hormone (TSH) and clinicopathologic features of the papillary thyroid microcarcinoma (PTMC) patients. Methods The thyroid nodules of 806 cases retrospectively that were for the first time hospitalized to our department in recent 5 years were collected, among them, postoperative pathological examination confirmed the diagnosis of PTMC in 403 cases, 403 cases of benign thyroid lesions, the history data of selected cases that meet the criterion of selection were retrospectively analyzed. TSH and anti thyroid globulin antibody (TGAb) levels between the 2 groups and the prevalence of ratio of PTMC in different TSH levels were compared. Univariate and multivariate analysis were performed to determine the risk factors of PTMC. Results The differences of preoperative TSH levels between the two groups was statistical significance (Z=–6.233,P=0.001), gender composition no statistical significance in two groups (χ²=3.246,P=0.072), and age was statistically significant (Z=–5.855,P=0.001). The constitution of ethnics of two groups was different (χ²=38.961,P=0.001). Logistic regression analysis display that age and TSH level were the independent risk factors of PTMC (age:OR=0.914,P=0.027; TSH:OR=4.662,P=0.008). Conclusions The level of serum TSH in PTMC patients is higher than in patients with benign thyroid nodules. TSH level is probably predictive of malignancy of PTMC.

Citation： Qiamixi , , , . Relationship between serum thyroid stimulating hormone and papillary thyroid micrcarcinomas. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(1): 64-69. doi: 10.7507/1007-9424.201603075 Copy

1.	?McLeod DS, Watters KF, Carpenter AD, et al. Thyotropin and thyroid cancer diagnosis: a systematic review and dose-respone meta-analysis. J Clin Endocrinol Metab, 2012, 97(8): 2682-2692.
2.	Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2. 2014. J Natl Compr Canc Netw, 2014, 12(12): 1671-1680; quiz 1680.
3.	Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013, 2013: 965212.
4.	Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg, 2008, 32(5): 747-753.
5.	Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Endocrinol Metab, 2008, 93(3): 809-814.
6.	Fiore E, Rago T, Provenzale MA, et al. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer, 2010, 17(1): 231-239.
7.	Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer, 2009, 16(4): 1065-1072.
8.	Cho JK, Kim JY, Jeong CY, et al. Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc, 2012, 82(5): 281-287.
9.	Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol, 2010, 36(5): 1067-1080.
10.	Zhu C, Zheng T, Kilfoy BA, et al. Abirth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid, 2009, 19(10): 1061-1066.
11.	Fighera TM, Perez CL, Faris N, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. Endokrynol Pol, 2015, 66(6): 480-485.
12.	Zafon C, Obiols G, Baena JA, et al. Preoperative thyrotropin serum concentrations gradually Increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J Thyroid Res, 2012, 2012: 530721.
13.	Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer, 2009, 16(4): 1251-1260.
14.	矯杰, 周迎生. 血清促甲狀腺激素水平與乳頭狀甲狀腺微小癌發生發展的相關性. 中華醫學雜志, 2015, 95(12): 908-911.
15.	閆慧嫻, 谷偉軍, 楊國慶, 等. 血清促甲狀腺激素與甲狀腺乳頭狀微小癌相關性研究. 中華內分泌代謝雜志, 2014, 30(8): 669-672.
16.	Shi L, Li Y, Guan H, et al. Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1 870 Chinese patients with thyroid nodules. Endocr J, 2012, 59(11): 973-980.
17.	Fiore E, Latrofa F, Vitti P. Iodine, thyroid autoimmunity and cancer. Eur Thyroid J, 2015, 4(1): 26-35.
18.	Haymart MR, Banerjee M, Yang D, et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer, 2013, 119(2): 259-265.
19.	Gerschpacher M, G?bl C, Anderwald C, et al. Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid, 2010, 20(4): 389-392.
20.	Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res, 2008, 150(1): 49-52.
21.	Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys, 2009, 55(2): 55-79.

1. ?McLeod DS, Watters KF, Carpenter AD, et al. Thyotropin and thyroid cancer diagnosis: a systematic review and dose-respone meta-analysis. J Clin Endocrinol Metab, 2012, 97(8): 2682-2692.
2. Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2. 2014. J Natl Compr Canc Netw, 2014, 12(12): 1671-1680; quiz 1680.
3. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013, 2013: 965212.
4. Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg, 2008, 32(5): 747-753.
5. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Endocrinol Metab, 2008, 93(3): 809-814.
6. Fiore E, Rago T, Provenzale MA, et al. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer, 2010, 17(1): 231-239.
7. Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer, 2009, 16(4): 1065-1072.
8. Cho JK, Kim JY, Jeong CY, et al. Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc, 2012, 82(5): 281-287.
9. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol, 2010, 36(5): 1067-1080.
10. Zhu C, Zheng T, Kilfoy BA, et al. Abirth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid, 2009, 19(10): 1061-1066.
11. Fighera TM, Perez CL, Faris N, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. Endokrynol Pol, 2015, 66(6): 480-485.
12. Zafon C, Obiols G, Baena JA, et al. Preoperative thyrotropin serum concentrations gradually Increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J Thyroid Res, 2012, 2012: 530721.
13. Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer, 2009, 16(4): 1251-1260.
14. 矯杰, 周迎生. 血清促甲狀腺激素水平與乳頭狀甲狀腺微小癌發生發展的相關性. 中華醫學雜志, 2015, 95(12): 908-911.
15. 閆慧嫻, 谷偉軍, 楊國慶, 等. 血清促甲狀腺激素與甲狀腺乳頭狀微小癌相關性研究. 中華內分泌代謝雜志, 2014, 30(8): 669-672.
16. Shi L, Li Y, Guan H, et al. Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1 870 Chinese patients with thyroid nodules. Endocr J, 2012, 59(11): 973-980.
17. Fiore E, Latrofa F, Vitti P. Iodine, thyroid autoimmunity and cancer. Eur Thyroid J, 2015, 4(1): 26-35.
18. Haymart MR, Banerjee M, Yang D, et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer, 2013, 119(2): 259-265.
19. Gerschpacher M, G?bl C, Anderwald C, et al. Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid, 2010, 20(4): 389-392.
20. Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res, 2008, 150(1): 49-52.
21. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys, 2009, 55(2): 55-79.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relationship between serum thyroid stimulating hormone and papillary thyroid micrcarcinomas

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content